Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.67 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077802 | 0.93 | L3MBTL1 (0.77) | HDAC6HDAC1HDAC8HDAC3L3MBTL1 | |
| SCHEMBL3030027 | 0.89 | HDAC6 (0.74) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL3024525 | 0.88 | HDAC6 (0.72) | HDAC6HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL3455449 | 0.86 | L3MBTL1 (0.69) | HDAC6HDAC1HDAC8HDAC3L3MBTL1 | |
| SCHEMBL10099566 | 0.86 | NR1H4 (0.69) | HDAC6HDAC1L3MBTL1LMNACXCR4 | |
| SCHEMBL6357065 | 0.85 | LMNA (0.70) | L3MBTL1LMNACXCR4MAPK14 | |
| SCHEMBL95283 | 0.85 | L3MBTL1 (0.67) | HDAC6HDAC1HDAC8HDAC3L3MBTL1 | |
| SCHEMBL10099594 | 0.85 | LMNA (0.70) | L3MBTL1LMNACXCR4MAPK14 | |
| SCHEMBL19630565 | 0.85 | EPHX2 (0.68) | HDAC6HDAC1L3MBTL1LMNACXCR4 | |
| SCHEMBL8429875 | 0.85 | LMNA (0.70) | L3MBTL1LMNACXCR4CYP3A4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | LESER-REIFF ULRIKE | 2004-10-28 | — | — | US | claimed |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HOFFMANN-LA ROCHE INC. | 2003-01-16 | — | — | US | claimed |
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | LESER-REIFF ULRIKE | 2004-10-28 | — | — | US | disclosed |
| US-6784173-B2 | ANTIPROLIFERATIVE AGENTS; ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-08-31 | — | — | US | disclosed |
| EP-1401824-A2 | AROMATIC HYDROXAMIC ACID DERIVATIVES USEFUL AS HDAC INHIBITORS | F. Hoffman-la Roche AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003011851-A2 | AROMATIC HYDROXAMIC ACID DERIVATIVES USEFUL AS HDAC INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2003-02-13 | — | — | WO | disclosed |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HOFFMANN-LA ROCHE INC. | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214862-A1 | Aromatic dicarboxylic acid derivatives | HDAC1, HDAC2, HDAC11 | HDAC6 13/4885HDAC1 1/4885HDAC8 6/4885 |
| US-20030013757-A1 | Aromatic dicarboxylic acid derivatives | HDAC1, HDAC2, HDAC11 | HDAC6 13/4885HDAC1 1/4885HDAC8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.